Table 2. BLCFA Exert Cytotoxicity to Cancer Cells in Vitro and in Vivo.

BLCFA	cancer types	in vitro or in vivo	animal model	cell lines	dosage	treatment period	ref
iso-15:0	prostate cancer	in vivo	MetaMouse orthotopic model		35, 70, and 105 mg/kg/day	43 days	(61)
iso-15:0	prostate cancer	in vitro		DU 145	0–60 μg/mL	48 h	(61)
anteiso-15:0	prostate cancer	in vitro		DU 145, PC3	0–120 μg/mL	72 h	(65)
iso-15:0	liver cancer	in vivo	MetaMouse orthotopic model		70 mg/kg/day	40 days	(61)
iso-15:0	Liver cancer	in vitro		SNU-423	0–60 μg/mL	48 h	(61)
iso-15:0	T-cell non-Hodgkin lymphomas	in vivo	BALB/c nude mice		70 mg/kg/day	15 days in EL4 cell xenografts; 30 days in Jurkat cell xenografts	(60)
iso-15:0	T-cell non-Hodgkin lymphomas	in vitro		Jurkat, Hut78, and EL4	0–80 μg/mL	24, 48, and 72 h	(60)
iso-15:0	bladder cancer	in vitro		T24, 5637, and UM-UC-3	0–140 μg/mL	12 and 24 h	(62)
iso-15:0	leukemia	in vitro		K-562	0–60 μg/mL	48 h	(61)
iso-15:0	colon cancer	in vitro		HCT 116	0–60 μg/mL	48 h	(61)
iso-15:0	small cell lung cancer	in vitro		NCI-H1688	0–60 μg/mL	48 h	(61)
anteiso-15:0	nonsmall cell lung cancer	in vitro		A549	0–120 μg/mL	72 h	(65)
anteiso-15:0	nonsmall cell lung cancer	in vitro		H1299	0–120 μg/mL	72 h	(65)
iso-15:0	pancreatic cancer	in vitro		BxPC-3	0–60 μg/mL	48 h	(61)
iso-15:0	gastric cancer	in vitro		NCI-SNU-1	0–60 μg/mL	48 h	(61)
iso-15:0	breast cancer	in vitro		MCF7	0–60 μg/mL	48 h	(61)
iso-15:0	breast cancer	in vitro		MCF7	50–400 μM	24, 48, and 72 h	(52)
anteiso-15:0	breast cancer	in vitro		MCF-7	0–120 μg/mL	72 h	(65)
iso-15:0	breast cancer	in vitro		SKBR-3	0.05–0.2 mM	24 h	(63)
iso-15:0	breast cancer	in vitro		SKBR-3	0–1 mM	72 h	(64)
iso-17:0	breast cancer	in vitro		MCF7	50–400 μM	24, 48, and 72 h	(52)